02/27/23 4:05 PMNasdaq : VERA conferenceslow floatVera Therapeutics to Participate in the Cowen 43rd Annual Health Care ConferenceVera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management teamRHEA-AIneutral
02/06/23 4:05 PMNasdaq : VERA offeringlow floatVera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common StockVera Therapeutics, Inc. (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the closing of itsRHEA-AIneutral
02/01/23 9:51 PMNasdaq : VERA offeringlow floatVera Therapeutics Announces Pricing of Public Offering of Class A Common StockVera Therapeutics, Inc., (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of itsRHEA-AIneutral
02/01/23 4:01 PMNasdaq : VERA offeringlow floatVera Therapeutics Announces Commencement of Public Offering of Class A Common StockVera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has commenced a public offering,RHEA-AIneutral
01/30/23 6:00 AMNasdaq : VERA clinical triallow floatVera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in ProteinuriaVera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current resources on the advancement of atacicept in IgA Nephropathy into a pivotal Phase 3 trial, extendingRHEA-AIneutral
01/26/23 8:00 AMNasdaq : VERA managementlow floatInnocoll Holdings Ltd. Appoints Kimball Hall as Chief Executive OfficerInnocoll Holdings Ltd., a global biotech pharmaceutical company and portfolio business of Gurnet Point Capital, today announced the appointment of Kimball Hall, a seasoned commercial operations executive, as President and Chief Executive Officer.RHEA-AIvery positive
01/25/23 8:00 AMNasdaq : VERA low floatVera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that it will host a virtual keyRHEA-AIneutral
01/03/23 4:01 PMNasdaq : VERA clinical triallow floatVera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA NephropathyAtacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data showing trend towards further reductions in proteinuria at week 36 Atacicept safety profile in IgAN patientsRHEA-AIneutral
12/20/22 4:05 PMNasdaq : VERA conferenceslow floatVera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceVera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management teamRHEA-AIneutral
11/22/22 7:30 AMNasdaq : VERA conferenceslow floatVera Therapeutics to Present at Upcoming Investor ConferencesVera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management teamRHEA-AIneutral